Aisling Capital Management as of March 31, 2022
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 21 positions in its portfolio as reported in the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 33.2 | $62M | 6.1M | 10.15 | |
| Monte Rosa Therapeutics (GLUE) | 11.1 | $21M | 1.5M | 14.02 | |
| Syndax Pharmaceuticals (SNDX) | 9.6 | $18M | 1.0M | 17.38 | |
| Harmony Biosciences Hldgs In (HRMY) | 9.0 | $17M | 343k | 48.65 | |
| Nuvation Bio Com Cl A (NUVB) | 7.2 | $13M | 2.5M | 5.26 | |
| Aclaris Therapeutics (ACRS) | 5.9 | $11M | 635k | 17.24 | |
| Elevation Oncology (ELEV) | 3.9 | $7.1M | 2.8M | 2.52 | |
| Talaris Therapeutics | 3.6 | $6.7M | 683k | 9.84 | |
| Verona Pharma Sponsored Ads (VRNA) | 3.6 | $6.6M | 1.3M | 4.99 | |
| Poseida Therapeutics I (PSTX) | 2.5 | $4.7M | 1.0M | 4.48 | |
| Aeglea Biotherapeutics | 2.1 | $3.9M | 1.7M | 2.30 | |
| Biomea Fusion (BMEA) | 1.9 | $3.6M | 799k | 4.46 | |
| Reneo Pharmaceuticals (RPHM) | 1.4 | $2.6M | 886k | 2.94 | |
| Spruce Biosciences (SPRB) | 1.3 | $2.4M | 1.2M | 2.01 | |
| Marker Therapeutics Ord | 0.7 | $1.4M | 3.1M | 0.44 | |
| Viracta Therapeutics (VIRX) | 0.7 | $1.4M | 289k | 4.76 | |
| Avrobio Ord (AVRO) | 0.7 | $1.3M | 1.0M | 1.32 | |
| Atreca Cl A Com (BCEL) | 0.7 | $1.2M | 388k | 3.17 | |
| Zosano Pharma Corporation Com New | 0.3 | $612k | 2.7M | 0.23 | |
| Obseva Sa | 0.3 | $596k | 395k | 1.51 | |
| Nabriva Therapeutics SHS | 0.0 | $80k | 191k | 0.42 |
